GSK, iTeos Score Phase II Win for Jemperli-TIGIT Combo in NSCLC
WEB3 days ago · In iTeos’ news release of the data drop, the partners called this effect a “clinically meaningful improvement,” noting that it represented an increase of around 30% versus Jemperli (dostarlimab) alone. ... Jemperli monotherapy counterparts, on the other hand, saw a 65% dip in circulating tumor DNA during this time frame. GSK and iTeos ...
GSK bags sought-after Jemperli okay in endometrial cancer
WEB6 days ago · The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for the...
GSK claims a first with Jemperli in endometrial cancer
WEBOct 30, 2023 · GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug.
FDA Approves Expanded Indication for Dostarlimab Plus Chemo
WEBAug 1, 2024 · US FDA expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment...
Jemperli (dostarlimab) trial continues to show unprecedented ... - GSK
WEBJun 3, 2024 · GSK plc (LSE/NYSE: GSK) today announced updated, longer-term results from the phase II supported collaborative study with Memorial Sloan Kettering Cancer Center (MSK) evaluating Jemperli (dostarlimab) as a first-line treatment—as an alternative to surgery—for mismatch repair deficient (dMMR) locally advanced rectal cancer.
FDA OKs Expanded Cancer Indication for Jemperli Plus Chemo
WEBAug 1, 2024 · The Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent, for all adult patients...
Jemperli (dostarlimab-gxly) plus chemotherapy approved in the …
WEBJul 31, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR ...
Jemperli (dostarlimab-gxly) trial continues to show …
WEBJun 3, 2024 · Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer ...
FDA approves dostarlimab-gxly with chemotherapy for …
WEBOn July 31, 2023, the Food and Drug Administration approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for primary...
GSK’s Jemperli (dostarlimab) plus chemotherapy approved as the …
WEBDec 11, 2023 · GSK’s Jemperli (dostarlimab) plus chemotherapy approved as the first and only frontline immuno-oncology treatment in the European Union for dMMR/MSI-H primary advanced or recurrent endometrial cancer. Download (PDF, 195.8KB) European Commission also converts previous conditional approval for Jemperli to full approval as a monotherapy for ...
Skip to content